Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.
The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.
Compass Therapeutics (NASDAQ: CMPX) provided a corporate update highlighting key developments in its oncology pipeline. The company's lead candidate tovecimig (CTX-009) is on track for Phase 2/3 top-line data in biliary tract cancer by Q1 2025. A new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, is advancing with IND submission expected by end of 2025.
Two Phase 2 biomarker trials are planned for mid-2025: tovecimig in DLL4-positive colorectal cancer and CTX-471 in NCAM/CD56 expressing tumors. The Phase 1 dose-escalation study of CTX-8371 has fully enrolled its third cohort, with preliminary data expected in H2 2025.
The company reports an estimated $127 million in cash and marketable securities at YE 2024, providing runway into Q1 2027.
Compass Therapeutics (CMPX) has appointed Barry Shin as Chief Financial Officer effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical leadership, including finance, operations, investment banking, and corporate advisory roles. Most recently, he served as EVP, COO & CFO at Trevena, Inc.
The appointment comes at a important time for Compass, with several key catalysts expected in 2025, including topline data readout for CTX-009 in the first quarter. CEO Thomas Schuetz highlighted Shin's expertise in financial planning, capital markets, and M&A as valuable assets for advancing CTX-009 and the company's portfolio of clinical and pre-clinical assets.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. The company's presentation is scheduled for Wednesday, December 4, 2024, from 9:50-10:10 AM EST. A webcast of the presentation will be available and archived for 90 days on Compass' Events page.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 PM ET, and at the Jefferies London Healthcare Conference in London on November 21 at 2:00 PM GMT. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX) reported Q3 2024 financial results and corporate updates. The company fully enrolled its Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected by Q1 2025. Net loss was $10.5 million ($0.08 per share) for Q3 2024. The company maintains a strong financial position with $135 million in cash and marketable securities, providing runway into Q1 2027. R&D expenses were $8.6 million, while G&A expenses increased to $3.6 million. Key pipeline developments include progress in CTX-471 trials with NCAM identified as a potential response biomarker, and advancement in CTX-8371's Phase 1 dose-escalation study.
Compass Therapeutics presented new biomarker data for CTX-471, their novel anti-CD137 agonist antibody, at the SITC Annual Meeting. The study revealed a significant correlation between neural cell adhesion molecule (NCAM/CD56) expression and patient response to CTX-471 monotherapy. The data comes from a Phase 1 trial in patients with advanced malignancies who previously progressed on PD-1/PD-L1 inhibitors. Key findings showed that tumor cell NCAM appears to enrich activated NK cells in the tumor microenvironment, suggesting NCAM's potential use as a selection marker for future clinical trials.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody', will be presented on Friday, November 8, 2024, from 9:00 AM to 7:00 PM CDT in Exhibit Halls AB. The presentation materials will be available on the company's website after the presentation concludes.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its participation in two major investor events in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 11:00 AM ET in New York. Additionally, Compass will participate in the Cantor Global Healthcare Conference on September 17 at 8:35 AM ET, also in New York.
Both presentations will be available via webcast, with links provided for each event. Investors and interested parties can access the webcasts through the specified URLs. The presentations will be archived for 90 days on Compass Therapeutics' Events page, allowing for extended viewing opportunities. These events provide a platform for Compass to showcase its progress in developing antibody-based therapeutics for oncology applications.
Compass Therapeutics (Nasdaq: CMPX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment of 150 patients in COMPANION-002 Phase 2/3 trial of CTX-009 for biliary tract cancers (BTC)
- Approved Investigator Sponsored Trial of CTX-009 in first-line BTC setting
- Encouraging preliminary data from COMPANION-003 Phase 2 trial of CTX-009 in colorectal cancer
- Planning Phase 2 monotherapy trial of CTX-471 with newly identified biomarker
- Completed first dosing cohort in Phase 1 study of CTX-8371
Q2 2024 net loss was $13.1 million ($0.10 per share). Cash position of $146 million provides runway into Q1 2027.